Literature DB >> 8861426

Management of arterial occlusive disease following radiation therapy.

G Andros1, P A Schneider, R W Harris, L B Dulawa, R W Oblath, S X Salles-Cunha.   

Abstract

Clinically significant arterial occlusive disease developed in 26 patients at between 5 months and 44 years (mean(s.d.) 10.7(12.0) years) following radiation therapy. Therapeutic radiation was associated with lesions of the carotid artery (nine patients), subclavian-axillary arteries (seven) and the abdominal aorta and its branches (10). Clinical presentations included transient ischemic attack, stroke, vertebrobasilar insufficiency, carotid bruit, upper- or lower-extremity ischemia and renovascular hypertension. Surgery for cerebrovascular insufficiency included carotid endarterectomy with vein patch, interposition grafting or subclavian-to-carotid bypass. Carotid or subclavian-to-axillary bypass was performed for upper-extremity ischemia. A combination of endarterectomy and Dacron or saphenous vein grafts was used for infrarenal reconstruction. Tunnels were placed orthotopically. Musculocutaneous flaps assisted in healing selected wounds. Ureteral catheters were useful adjuncts in abdominal vascular reconstructions. There were no operative deaths, strokes or amputations. One patient had recurrent transient ischemic attacks following subclavian-to-carotid bypass. The mean(s.d.) postoperative follow-up was 48.1(39.6) months. Patients presenting with end-organ ischemia following radiation therapy can be managed successfully with aggressive surgical revascularization using a broad spectrum of reconstructive techniques.

Entities:  

Mesh:

Year:  1996        PMID: 8861426     DOI: 10.1016/0967-2109(96)82304-0

Source DB:  PubMed          Journal:  Cardiovasc Surg        ISSN: 0967-2109


  1 in total

1.  Arterial occlusive disease complicating radiation therapy of cervical cancer.

Authors:  Ki-Bum Won; Byeong-Keuk Kim; Young-Guk Ko; Myeong-Ki Hong; Donghoon Choi; Yangsoo Jang
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.